Advertisement

Journal of Gastrointestinal Surgery

, Volume 11, Issue 11, pp 1521–1528 | Cite as

Underexpression of Mineralocorticoid Receptor in Colorectal Carcinomas and Association with VEGFR-2 Overexpression

  • Francesco Di FabioEmail author
  • Carlos Alvarado
  • Agnieszka Majdan
  • Adrian Gologan
  • Linda Voda
  • Elliot Mitmaker
  • Lenore K. Beitel
  • Philip H. Gordon
  • Mark Trifiro
Article

Abstract

Background

The human mineralocorticoid receptor (MR) is a steroid receptor widely expressed in colorectal mucosa. A significant role for the MR in the reduction of vascular endothelial growth factor receptor-2 (VEGFR-2) mRNA levels has been demonstrated in vitro. To evaluate a potential contribution of MR to colorectal carcinoma progression, we analyzed the expression of MR in relation to VEGFR-2.

Methods

Fresh human colorectal cancer tissue and adjacent normal mucosa were harvested from 48 consecutive patients. MR and VEGFR-2 mRNA expression levels were determined by real-time reverse transcriptase–polymerase chain reaction and correlated with clinicopathological parameters.

Results

A decline of MR expression was observed in all carcinomas compared to normal mucosa. Expression of MR was a median of 11-fold lower in carcinoma compared to the normal mucosa, irrespective of the location, size, stage, and differentiation. MR was a median of 20-fold underexpressed in carcinomas with VEGFR-2 overexpression vs only 9-fold in carcinomas with VEGFR-2 underexpression (p = 0.035, Mann–Whitney test).

Conclusions

These findings support the hypothesis that reduction of MR expression may be one of the early events involved in colorectal carcinoma progression. The inverse association between MR and VEGFR-2 expression in carcinoma suggests a potential tumor-suppressive function for MR.

Keywords

Colorectal cancer Mineralocorticoid receptor Vascular endothelial growth factor receptor-2 Angiogenesis 

Notes

Acknowledgements

The authors wish to thank Carmela Masella, Lianna Mantley, and Rita Notte for their valuable secretarial assistance in the course of this study.

References

  1. 1.
    Rogerson FM, Brennan FE, Fuller PJ. Dissecting mineralocorticoid receptor structure and function. J Steroid Biochem Mol Biol 2003;85:389–396.PubMedCrossRefGoogle Scholar
  2. 2.
    Sheppard KE. Nuclear receptors. II. Intestinal corticosteroid receptors. Am J Physiol Gastrointest Liver Physiol 2002;282:G742–746.PubMedGoogle Scholar
  3. 3.
    Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47:312–318.PubMedCrossRefGoogle Scholar
  4. 4.
    Schiffrin EL. The many targets of aldosterone. Hypertension 2004;43:938–940.PubMedCrossRefGoogle Scholar
  5. 5.
    Oberleithner H, Schneider SW, Albermann L, Hillebrand U, Ludwig T, Riethmuller C, Shahin V, Schafer C, Schillers H. Endothelial cell swelling by aldosterone. J Membr Biol 2003;196:163–172.PubMedCrossRefGoogle Scholar
  6. 6.
    Oberleithner H, Riethmuller C, Ludwig T, Hausberg M, Schillers H. Aldosterone remodels human endothelium. Acta Physiol 2006;187:305–312.CrossRefGoogle Scholar
  7. 7.
    Marumo T, Uchimura H, Hayashi M, Hishikawa K, Fujita T. Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 2006;48:490–496.PubMedCrossRefGoogle Scholar
  8. 8.
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Fidler LJ, Ellis LM. The implication of angiogenesis for the biology and the therapy of cancer metastasis. Cell 1994;79:185–188.PubMedCrossRefGoogle Scholar
  10. 10.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.PubMedCrossRefGoogle Scholar
  11. 11.
    Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling—in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–371.PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.PubMedCrossRefGoogle Scholar
  13. 13.
    Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma–carcinoma sequence during colorectal cancer progression. J Pathol 2003;200:183–194.PubMedCrossRefGoogle Scholar
  15. 15.
    Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O’Dwyer ST, Jayson GC. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 2006;42:112–117.PubMedCrossRefGoogle Scholar
  16. 16.
    Huang J, Qi R, Quackenbush J, Dauway E, Lazaridis E, Yeatman T. Effects of ischemia on gene expression. J Surg Res 2001;99:222–227.PubMedCrossRefGoogle Scholar
  17. 17.
    Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 2006;47:609–613.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen W, Valamanesh F, Mirshahi T, Soria J, Tang R, Agarwal MK, Mirshahi M. Aldosterone signaling modifies capillary formation by human bone marrow endothelial cells. Vascul Pharmacol 2004;40:269–277.PubMedCrossRefGoogle Scholar
  19. 19.
    Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237–268.PubMedGoogle Scholar
  20. 20.
    Hyder SM, Stancel GM. Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histol Histopathol 2000;15:325–334.PubMedGoogle Scholar
  21. 21.
    Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 1995;36:139–155.PubMedCrossRefGoogle Scholar
  22. 22.
    Garmy-Susini B, Varner JA. Circulating endothelial progenitor cells. Br J Cancer 2005;93:855–858.PubMedCrossRefGoogle Scholar
  23. 23.
    Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006;66:632–637.PubMedCrossRefGoogle Scholar
  24. 24.
    Takahashi K, Sasano H, Fukushima K, Hirasawa G, Miura H, Sasaki I, Matsuno S, Krozowski ZS, Nagura H. 11 beta-hydroxysteroid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms. Anticancer Res 1998;18:3381–3388.PubMedGoogle Scholar
  25. 25.
    Sugai T, Habano W, Jiao YF, Tsukahara M, Takeda Y, Otsuka K, Nakamura S. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 2006;8:193–201.PubMedCrossRefGoogle Scholar
  26. 26.
    Klauber N, Browne F, Anand-Apte B, D’Amato RJ. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 1996;94:2566–2571.PubMedGoogle Scholar
  27. 27.
    Miternique-Grosse A, Griffon C, Siegel L, Neuville A, Weltin D, Stephan D. Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats. J Hypertens 2006;24:2207–2213.PubMedCrossRefGoogle Scholar
  28. 28.
    Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodelling in dogs with heart failure. Circulation 2002;106:2967–2972.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2007

Authors and Affiliations

  • Francesco Di Fabio
    • 1
    • 4
    • 7
    Email author
  • Carlos Alvarado
    • 4
  • Agnieszka Majdan
    • 2
    • 4
  • Adrian Gologan
    • 3
  • Linda Voda
    • 2
    • 4
  • Elliot Mitmaker
    • 4
  • Lenore K. Beitel
    • 2
    • 4
    • 5
    • 6
  • Philip H. Gordon
    • 1
  • Mark Trifiro
    • 2
    • 4
    • 5
    • 6
  1. 1.Department of Colon and Rectal SurgerySir Mortimer B. Davis Jewish General HospitalMontrealCanada
  2. 2.Department of EndocrinologySir Mortimer B. Davis Jewish General HospitalMontrealCanada
  3. 3.Department of PathologySir Mortimer B. Davis Jewish General HospitalMontrealCanada
  4. 4.Lady Davis Institute for Medical ResearchSir Mortimer B. Davis Jewish General HospitalMontrealCanada
  5. 5.Department of Human GeneticsMcGill UniversityMontrealCanada
  6. 6.Department of MedicineMcGill UniversityMontrealCanada
  7. 7.Cattedra di Chirurgia GeneraleUniversity of Brescia School of MedicineBresciaItaly

Personalised recommendations